Evidence map›Paper›PMID 37306074›Full record

ArticleACS nano2023

Multivalent Carbohydrate Nanocomposites for Tumor Microenvironment Remodeling to Enhance Antitumor Immunity.

Gyu Hwan Hyun, Da-Hye Jeong, Yoon Young Yang, In Ho Cho, Yu-Jin Ha, Xiaohui Xing, D Wade Abbott, Yves S Y Hsieh, Yun Pyo Kang, Jong-Ho Cha and 4 more

Open access · hybridAbstract read
In one paragraph

Article in ACS nano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Gyu Hwan HyunCollege of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Da-Hye JeongDepartment of Biochemistry, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
Yoon Young YangCollege of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
In Ho ChoCollege of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Yu-Jin HaDepartment of Biochemistry, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
Xiaohui XingLethbridge Research and Development Centre, Agriculture and Agri-Food Canada, Lethbridge, Alberta T1J 4B1, Canada.
D Wade AbbottLethbridge Research and Development Centre, Agriculture and Agri-Food Canada, Lethbridge, Alberta T1J 4B1, Canada.
Yves S Y HsiehDivision of Glycoscience, Department of Chemistry, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, AlbaNova University Centre, Stockholm SE10691, Sweden.ORCID 0000-0002-0968-5793
Yun Pyo KangCollege of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Jong-Ho ChaDepartment of Biomedical Science, College of Medicine, and Program in Biomedical Sciences and Engineering, Inha University, Incheon 22332, Republic of Korea.
Soon-Sun HongDepartment of Biomedical Science, College of Medicine, and Program in Biomedical Sciences and Engineering, Inha University, Incheon 22332, Republic of Korea.
Seul Ji LeeCollege of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
You-Sun KimDepartment of Biochemistry, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
Sung Won KwonCollege of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.ORCID 0000-0001-7161-4737
Seoul National University · KRAjou University · KRAgriculture and Agri-Food Canada · CAInha University · KRAlbaNova · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current cancer immunotherapeutic strategies mainly focus on remodeling the tumor microenvironment (TME) to make it favorable for antitumor immunity. Increasing attention has been paid to developing innovative immunomodulatory adjuvants that can restore weakened antitumor immunity by conferring immunogenicity to inflamed tumor tissues. Here, a galactan-enriched nanocomposite (Gal-NC) is developed from native carbohydrate structures through an optimized enzymatic transformation for effective, stable, and biosafe innate immunomodulation. Gal-NC is characterized as a carbohydrate nanoadjuvant with a macrophage-targeting feature. It is composed of repeating galactan glycopatterns derived from heteropolysaccharide structures of plant origin. The galactan repeats of Gal-NC function as multivalent pattern-recognition sites for Toll-like receptor 4 (TLR4). Functionally, Gal-NC-mediated TLR activation induces the repolarization of tumor-associated macrophages (TAMs) toward immunostimulatory/tumoricidal M1-like phenotypes. Gal-NC increases the intratumoral population of cytotoxic T cells, the main effector cells of antitumor immunity, via re-educated TAMs. These TME alterations synergistically enhance the T-cell-mediated antitumor response induced by αPD-1 administration, suggesting that Gal-NC has potential value as an adjuvant for immune checkpoint blockade combination therapies. Thus, the Gal-NC model established herein suggests a glycoengineering strategy to design a carbohydrate-based nanocomposite for advanced cancer immunotherapies.

Indexed as

NeoplasmsTumor MicroenvironmentAdjuvants, ImmunologicHumansImmunomodulationImmunotherapyMacrophagesAdjuvants, Immunologiccancer immunotherapycarbohydratesmacrophagesmultivalencypolysaccharidestumor microenvironment

Identifiers

PMID37306074
PMCPMC10311601
OpenAlexW4380291901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.